The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Champions Oncology's 9-Day RSI or its related term are showing as below:
CSBR's 9-Day RSI is ranked better than 83.76% of 1422
companies
in the Biotechnology industry
Industry Median: 51.47
vs CSBR: 37.50
Champions Oncology (NAS:CSBR) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Champions Oncology 9-Day RSI Related Terms
CSBR vs SEER, RLYB, FBIO: 9-Day RSI Comparison
For the Biotechnology subindustry, Champions Oncology's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Champions Oncology's 9-Day RSI falls into.
Champions Oncology (NAS:CSBR) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (CSBR) has a 9-Day RSI of 37.50 as of Jul. 05, 2026. According to the industry distribution chart, Champions Oncology ranks #231 out of 1422 companies in the Biotechnology industry, placing it in the top 16.2%.
Is Champions Oncology's 9-Day RSI too high?
Champions Oncology's current 9-Day RSI is 37.50. The Biotechnology industry median 9-Day RSI is 51.47. Champions Oncology's value of 37.50 is 27.1% below this industry median. Based on the distribution chart, Champions Oncology ranks #231 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's 9-Day RSI compare to SEER and RLYB?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #231 out of 1422 companies for 9-Day RSI. This places Champions Oncology in the top 16% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 51.47. Champions Oncology's value of 37.50 is 27.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 51.47, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current 9-Day RSI of 37.50 is 27.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 51.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current 9-Day RSI is 37.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.64, compared to a current price of $5.76 — trading 13.3% below its estimated fair value. The current 9-Day RSI is 37.50 and 27.1% below the Biotechnology industry median of 51.47. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Champions Oncology (CSBR), the current 9-Day RSI is 37.50 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $5.76 is trading 13.3% below its estimated GF Value™ of $6.64.
GuruFocus considers Champions Oncology to be Modestly Undervalued.
Key valuation signals for CSBR:
9-Day RSI: 37.50
GF Value™: $6.64 vs. price of $5.76 (13.3% below fair value)
Industry Position: 27.1% below the Biotechnology median (#231 of 1422)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 